- Biogen is collaborating with Happify Health to support people
living with Multiple Sclerosis (MS)
- Happify Health’s platform supports the MS patient care journey,
keeps patients abreast of treatment advances, helps support
medication adherence, promotes holistic wellness goals, connects
users with other members of the MS community, and gives them access
to original content authored by experts in neurology and mental
health
- Biogen has a leading portfolio of medicines to treat MS and is
committed to pioneering in digital health
Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com),
the Intelligent Healing Company™, today announced a collaboration
to provide a digital solution for patient education and engagement,
powered by artificial intelligence (AI), to support people living
with multiple sclerosis (MS). Through this collaboration, Biogen
and Happify Health will help people with MS manage their care
journey, improve their wellbeing, learn about treatment options,
consult with experts, and connect with other people in the MS
community for support.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220622005194/en/
More than 2.3 million people live with MS globally, including
over 1 million people in the United States, according to the
National MS Society. Women are two to three times more likely to
develop MS than men1.
“This collaboration is one of many ways we are focused on
supporting patients by meeting them where they are. The combination
of Biogen’s expertise in neuroscience and our commitment to digital
health, along with Happify Health’s AI and digital therapeutic
capabilities will help drive a connected and comprehensive
experience that allows patients to feel supported throughout their
journey,” said Jason Hawbecker, Head of Strategic Partnerships
& Collaborations at Biogen. “We are excited about the potential
of this partnership to provide overall support for the MS
community.”
The Happify Health solution, which brings together a digital
tool configured for MS and a care community (Kopa), offers holistic
health and wellness support, with access to neurology providers
(doctors, nurse practitioners, physicians assistants and nurses) as
well as mental health specialists, dietitians, and rehabilitation
professionals. The online community that recently launched provides
a place for those living with MS to ask experts questions and
discuss the physical and mental challenges they are facing with
patients in similar stages. Happify Health uses its proprietary AI
technology to personalize content to patients’ life stages,
symptoms and interests.
“It can be challenging for people living with MS to stay
up-to-date with the latest treatments, interpret new symptoms, or
investigate changes in their health that may or may not be related
to MS,” said Ofer Leidner, President of Happify Health. “We are
providing the MS community with a solution configured to
accommodate their specific needs, as well as opportunities to
engage with experts, receive curated content, and discuss disease
management with other community members. We are very excited to
partner with Biogen on this opportunity given their leadership in
the MS space.”
Biogen, a global leader in developing treatments for people
living with serious neurological and neurodegenerative diseases,
will provide support for the MS platform, including educational
content and resources for the patient care journey. The company is
a global leader in treating MS with a portfolio of medicines to
treat relapsing forms of MS, characterized by periods where
symptoms subside, with full or partial recovery, and there is no
disease progression between attacks.
In addition to psoriasis and maternal health, MS is the third
therapeutic area to be addressed through Happify Health's unique
Sequence™ approach. Sequences are configured to support specific
medical conditions and weave together components like
evidence-based digital therapeutics, online communities, and
coaching in one unified platform, with recommendations tailored for
each individual.
About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and
delivers worldwide innovative therapies for people living with
serious neurological diseases as well as related therapeutic
adjacencies. One of the world’s first global biotechnology
companies, Biogen was founded in 1978 by Charles Weissmann, Heinz
Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter
Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of
medicines to treat multiple sclerosis, has introduced the first
approved treatment for spinal muscular atrophy, and developed the
first and only approved treatment to address a defining pathology
of Alzheimer’s disease. Biogen is also commercializing biosimilars
and focusing on advancing one of the industry’s most diversified
pipelines in neuroscience that will transform the standard of care
for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social media -
Twitter, LinkedIn, Facebook, YouTube.
About Happify Health
Happify Health is The Intelligent Healing Company™. We shorten
the distance between need and care by configuring personalized
digital therapeutics and care solutions at scale for the modern
healthcare cloud. Our platform integrates AI with empathy, making
healing more personal, precise, and connected for the entire care
journey. We deploy a full spectrum of clinical-grade care
solutions—including Digital Therapeutics, Coaching, Community, and
Well-being products—for pharma, health plans, enterprises, and
individuals everywhere. Our global platform is available in 10
languages, supports chronic conditions, and covers more than 18
million lives. For more information, visit HappifyHealth.com.
Biogen Safe Harbor
This news release contains forward-looking statements, including
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, about the
potential impact of artificial intelligence with respect to
clinical and health outcomes; the potential benefits from early
identification of disease; the potential benefits and results that
may be achieved through our collaboration with Happify Health; the
potential of our commercial business and pipeline programs; and our
strategy and plans. These statements may be identified by words
such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would” and other words and terms of similar
meaning. You should not place undue reliance on these statements,
or the scientific data presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation, the risks of
unexpected costs or delays; the risk of other unexpected hurdles;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; regulatory authorities may require
additional information or further studies; third party
collaboration risks; and the direct and indirect impacts of the
ongoing COVID-19 pandemic on our business, results of operations
and financial condition. The foregoing sets forth many, but not
all, of the factors that could cause actual results to differ from
our expectations in any forward-looking statement. Investors should
consider this cautionary statement as well as the risk factors
identified in our most recent annual or quarterly report and in
other reports we have filed with the U.S. Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this news release. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
References:
- National Multiple Sclerosis Society MS FAQ
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220622005194/en/
MEDIA CONTACTS: Biogen Ashleigh Koss + 1 908 205 2572
public.affairs@biogen.com
Happify Health Erin Bocherer + 1 678-294-2258
erin@cogentacom.com
INVESTOR CONTACT: Biogen Mike Hencke +1 781 464 2442
IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024